• Je něco špatně v tomto záznamu ?

Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study

RR. Jones, I. Turkoz, M. Ait-Tihyaty, A. DiBernardo, MK. Houtchens, EK. Havrdová

. 2024 ; 33 (4) : 480-490. [pub] 20240201

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, klinické zkoušky, fáze III, práce podpořená grantem, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014482

Background: Multiple sclerosis (MS) is threefold more prevalent in women than men. However, sex-specific efficacy analysis for MS disease-modifying therapies is not typically performed. Methods:Post hoc analyses of data from female patients enrolled in the phase 3, double-blind OPTIMUM study of relapsing MS were carried out. Eligible adults were randomized to ponesimod 20 mg or teriflunomide 14 mg once daily for up to 108 weeks. The primary endpoint was annualized relapse rate (ARR); secondary endpoints included change in symptom domain of Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) at week 108, number of combined unique active lesions (CUALs) per year on magnetic resonance imaging, and time to 12- and 24-week confirmed disability accumulation (CDA). Results: A total of 735 female patients (581 of childbearing potential) were randomized to ponesimod (n = 363, 49.4%) or teriflunomide (n = 372, 50.6%). Relative risk reduction in the ARR for ponesimod versus teriflunomide was 33.1% (mean, 0.192 vs. 0.286, respectively; p < 0.002). Mean difference in FSIQ-RMS for ponesimod versus teriflunomide was -4.34 (0.12 vs. 4.46; p = 0.002); rate ratio in CUALs per year, 0.601 (1.45 vs. 2.41; p < 0.0001), and hazard ratio for time to 12- and 24-week CDA risk estimates, 0.83 (10.7% vs. 12.9%; p = 0.38) and 0.91 (8.8% vs. 9.7%; p = 0.69), respectively. Incidence of treatment-emergent adverse events was similar between treatment groups (89.0% and 90.1%). Conclusions: Analyses demonstrate the efficacy and safety of ponesimod, versus active comparator, for women with relapsing MS, supporting data-informed decision-making for women with MS. Clinical Trial Registration Number: NCT02425644.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014482
003      
CZ-PrNML
005      
20240905133906.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1089/jwh.2023.0037 $2 doi
035    __
$a (PubMed)38301149
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jones, Robyn R $u Office of Chief Medical Officer, Johnson & Johnson, New Brunswick, New Jersey, USA
245    10
$a Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study / $c RR. Jones, I. Turkoz, M. Ait-Tihyaty, A. DiBernardo, MK. Houtchens, EK. Havrdová
520    9_
$a Background: Multiple sclerosis (MS) is threefold more prevalent in women than men. However, sex-specific efficacy analysis for MS disease-modifying therapies is not typically performed. Methods:Post hoc analyses of data from female patients enrolled in the phase 3, double-blind OPTIMUM study of relapsing MS were carried out. Eligible adults were randomized to ponesimod 20 mg or teriflunomide 14 mg once daily for up to 108 weeks. The primary endpoint was annualized relapse rate (ARR); secondary endpoints included change in symptom domain of Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) at week 108, number of combined unique active lesions (CUALs) per year on magnetic resonance imaging, and time to 12- and 24-week confirmed disability accumulation (CDA). Results: A total of 735 female patients (581 of childbearing potential) were randomized to ponesimod (n = 363, 49.4%) or teriflunomide (n = 372, 50.6%). Relative risk reduction in the ARR for ponesimod versus teriflunomide was 33.1% (mean, 0.192 vs. 0.286, respectively; p < 0.002). Mean difference in FSIQ-RMS for ponesimod versus teriflunomide was -4.34 (0.12 vs. 4.46; p = 0.002); rate ratio in CUALs per year, 0.601 (1.45 vs. 2.41; p < 0.0001), and hazard ratio for time to 12- and 24-week CDA risk estimates, 0.83 (10.7% vs. 12.9%; p = 0.38) and 0.91 (8.8% vs. 9.7%; p = 0.69), respectively. Incidence of treatment-emergent adverse events was similar between treatment groups (89.0% and 90.1%). Conclusions: Analyses demonstrate the efficacy and safety of ponesimod, versus active comparator, for women with relapsing MS, supporting data-informed decision-making for women with MS. Clinical Trial Registration Number: NCT02425644.
650    _2
$a lidé $7 D006801
650    12
$a toluidiny $x terapeutické užití $x škodlivé účinky $7 D014052
650    12
$a hydroxybutyráty $7 D006885
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nitrily $x terapeutické užití $x škodlivé účinky $7 D009570
650    12
$a krotonáty $x terapeutické užití $x škodlivé účinky $7 D003437
650    _2
$a dospělí $7 D000328
650    12
$a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    _2
$a thiazoly $x škodlivé účinky $x terapeutické užití $7 D013844
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a magnetická rezonanční tomografie $7 D008279
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Turkoz, Ibrahim $u Department of Statistics and Decision Sciences, Janssen Research & Development, LLC, Titusville, New Jersey, USA
700    1_
$a Ait-Tihyaty, Maria $u Global Medical Affairs, Janssen Research & Development, LLC, Titusville, New Jersey, USA $1 https://orcid.org/0000000219834334
700    1_
$a DiBernardo, Allitia $u Global Medical Affairs, Janssen Research & Development, LLC, Titusville, New Jersey, USA
700    1_
$a Houtchens, Maria K $u Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA
700    1_
$a Havrdová, Eva Kubala $u Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic
773    0_
$w MED00008031 $t Journal of women's health $x 1931-843X $g Roč. 33, č. 4 (2024), s. 480-490
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38301149 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133900 $b ABA008
999    __
$a ok $b bmc $g 2143936 $s 1226348
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 33 $c 4 $d 480-490 $e 20240201 $i 1931-843X $m Journal of women's health $n J Womens Health (Larchmt) $x MED00008031
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace